Table 1.
Average immunolabeling levels of proliferative and apoptotic markers (% of total cells).
Fig 1.
Immunolabeling of proliferative markers.
Representative microphotographs of phosphorylated histone H3 (pHH3; 1) and cyclin D1 immunolabeling (2) in normal thyroid tissue (a) and the various types of papillary thyroid carcinomas: encapsulated (b) and unencapsulated (c) follicular variant of papillary thyroid carcinoma (FVPTC), well differentiated tumor of unknown malignant potential (WDT-UMP; d), papillary microcarcinoma (PMC; e) and metastatic papillary thyroid carcinoma (f). Bars correspond to 50 μm.
Fig 2.
Immunolabeling of apoptosis markers.
Representative microphotographs of cleaved caspase-3 (1) and bcl-2 (2) immunolabeling in normal thyroid tissue (a) and the various types of papillary thyroid carcinomas: encapsulated (b) and unencapsulated (c) follicular variant of papillary thyroid carcinoma (FVPTC), well differentiated tumor of unknown malignant potential (WDT-UMP; d), papillary microcarcinoma (PMC; e) and metastatic papillary thyroid carcinoma (f). Bars correspond to 50 μm.
Fig 3.
Proportion of tumor cells immunolabeled for phosphorylated histone H3.
The percentage of tumor cells showing phosphorylated histone H3 immunolabeling is indicated in normal thyroid tissue and each case of the various types of papillary thyroid carcinomas: encapsulated and unencapsulated follicular variant of papillary thyroid carcinoma (FVPTC), well differentiated tumor of unknown malignant potential (WDT-UMP), papillary microcarcinoma (PMC) and metastatic papillary thyroid carcinoma (metastatic PTC). Bars indicate the medians. *, p<0.05. The large asterisk above normal thyroid tissue indicates significant difference between the normal tissue and any other variant of PTC.
Fig 4.
Proportion of tumor cells immunolabeled for cyclin D1.
The percentage of tumor cells showing cyclin D1 immunolabeling is indicated in normal thyroid tissue and each case of the various types of papillary thyroid carcinomas: encapsulated and unencapsulated follicular variant of papillary thyroid carcinoma (FVPTC), well differentiated tumor of unknown malignant potential (WDT-UMP), papillary microcarcinoma (PMC) and metastatic papillary thyroid carcinoma (metastatic PTC). Bars indicate the medians. *, p<0.05. The large asterisk above normal thyroid tissue indicates significant difference between the normal tissue and any other variant of PTC.
Fig 5.
Proportion of tumor cells immunolabeled for cleaved caspase-3.
The percentage of tumor cells showing cleaved caspase-3 immunolabeling is indicated in normal thyroid tissue and each case of the various types of papillary thyroid carcinomas: encapsulated and unencapsulated follicular variant of papillary thyroid carcinoma (FVPTC), well differentiated tumor of unknown malignant potential (WDT-UMP), papillary microcarcinoma (PMC) and metastatic papillary thyroid carcinoma (metastatic PTC). Bars indicate the medians. *, p<0.05. The large asterisk above normal thyroid tissue indicates significant difference between the normal tissue and any other variant of PTC.
Fig 6.
Proportion of tumor cells immunolabeled for bcl-2.
The percentage of tumor cells showing bcl-2 immunolabeling is indicated in normal thyroid tissue and each case of the various types of papillary thyroid carcinomas: encapsulated and unencapsulated follicular variant of papillary thyroid carcinoma (FVPTC), well differentiated tumor of unknown malignant potential (WDT-UMP), papillary microcarcinoma (PMC) and metastatic papillary thyroid carcinoma (metastatic PTC). Bars indicate the medians. *, p<0.05.